Safety Pharmacology Society: 7th Annual Meeting 19-20 September 2007, Edinburgh, UK

Expert Opinion on Drug Safety

Volumn 7, Issue 1, 2008, Pages 91-100

  Cavero, Icilio ^a  

^a NONE   (Italy)

Author keywords

Drug discovery; Ethical obligations; Non clinical data; Pharmaceutical industry; Respiratory system safety; Risk management; Safety pharmacology; Torcetrapib safety issues; Translation

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CD28 ANTIGEN; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DRUG; HISTAMINE H3 RECEPTOR ANTAGONIST; LAMOTRIGINE; METHACHOLINE; NICORANDIL; PRIMIDONE; TGN 1412; TORCETRAPIB;

AIRWAY OBSTRUCTION; ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; BLOOD GAS ANALYSIS; BLURRED VISION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CLINICAL TRIAL; COLOR VISION DEFECT; CONFERENCE PAPER; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; ELECTROLYTE BLOOD LEVEL; EYE DISEASE; HEADACHE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; LOOSE FECES; LUNG COMPLIANCE; LUNG RESISTANCE; MEDICAL SOCIETY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PHOTOPHOBIA; POSTMARKETING SURVEILLANCE; POTASSIUM BLOOD LEVEL; QT PROLONGATION; RESPIRATION DEPRESSION; RISK MANAGEMENT; SIDE EFFECT; SODIUM BLOOD LEVEL; TOXICITY TESTING; TREND STUDY; UNSTABLE ANGINA PECTORIS; VALIDATION STUDY; VISUAL ACUITY; VOMITING;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; SCOTLAND; SOCIETIES, SCIENTIFIC;

EID: 38949100022     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.1.91     Document Type: Conference Paper

References (21)

1. Cavero I. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society, 13 February, 2007, Pfizer, Sandwich, Kent, UK. Expert Opin Drug Saf 2007;3(5):217-24
2. Cavero I. Optimizing the preclinical/clinical interface: an Informa Life Science conference 12 - 13 December, 2006, London, UK. Expert Opin Drug Saf 2007;3(2):217-24
3. Cavero I. Safety Pharmacology Society: 6th Annual Meeting 26 - 28 September, 2006, San Diego, USA. Expert Opin Drug Saf 2007;6(1):87-92
4. Cavero I, Crumb W. Safety Pharmacology Society: 5th Annual Meeting 27 - 29 September, 2005, Mannheim, Germany. Expert Opin Drug Saf 2006;5(1):181-5
5. Autobiography of Sir James W Black - The Nobel Prize in Physiology or Medicine 1988. Available at: URL: nobelprize.org/nobel∥izes/medicine/ laureates/1988/black-autobio.html [last accessed December 2007]
6. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. (2005) Available at: URL:www.ich.org/LOB/media/MEDIA2192.pdf [last accessed December 2007]
7. Safety pharmacology studies for human pharmaceuticals. S7A (2000) Available at: URL: www.ich.org/LOB/media/MEDIA504.pdf [last accessed December 2007]
8. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14 Available at: URL: www.ich.org/LOB/media/MEDIA1476.pdf [last accessed December 2007]
9. Howes LG, Kostner K. The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 2007;16(10):1509-16
10. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-21
11. Authier S, Legaspi M, Gauvin, et al. Validation of respiratory safety pharmacology models: conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods 2008;57(1):52-60
12. Desilvey DL, Moss AJ. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. Ann Intern Med 1980;93(1):53-4
13. Aizawa Y, Uchiyama H, Yamaura, et al. Effects of the ATP-sensitive K channel opener nicorandil on the QT interval and the effective refractory period in patients with congenital long QT syndrome. Investigator group for K-channel openers and arrhythmias. J Electrocardiol 1998;31(2):117-23
14. Borggrefe M, Wolpert C, Antzelevitch C, et al. Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol 2005;38(4 Suppl):75-80
15. Zhou J, Augelli-Szafran CE, Bradley JA, et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005;68(3):876-84
16. Robert E, Delye B, Aya G, et al. Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart J Cardiovasc Pharmacol 1997;29(1):109-18
17. Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004;110(24):3661-6
18. Gussak I, Brugada P, Brugada J, et al. ECG phenomenon of idiopathic and paradoxical short QT intervals. Card Electrophysiol Rev 2002;6(1-2):49-53
19. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005;96(7):800-7
20. Prusky GT, Alam NM, Beckman S, et al. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Sci 2004;45(12):4611-16
21. Rader DJ. Illuminating HDL-Is it still a viable therapeutic target? N Engl J Med 2007 357(21):2180-3